FDA grants Breakthrough Therapy Designation for Roche’s investigational cancer immunotherapy MPDL3280A
2 February 2015 | By Roche
US FDA has granted Breakthrough Therapy Designation for Roche’s investigational cancer immunotherapy MPDL3280A (anti-PDL1) in non-small cell lung cancer...